MKMingqiang Kang

Mingqiang Kang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mingqiang Kang has a total of 72 co-authors. Here are the top co-authors by number of shared publications:

  • Zhinuan Hong

    Fujian Med Univ, Union Hosp, Dept Thorac Surg, Xinquan Rd 29th, Fuzhou 350001, Peoples R China

    9 shared publications
  • Zhi-Nuan Hong

    Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China

    8 shared publications
  • Kai Weng

    Fujian Med Univ, Union Hosp, Dept Thorac Surg, Xinquan Rd 29th, Fuzhou 350001, Peoples R China

    7 shared publications
  • Kaiming Peng

    Department II of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou 350000, China

    7 shared publications
  • Zhixin Huang

    Department of Thoracic Surgery, Fujian Medical University Union Hospital, Gulou, Fuzhou, People’s Republic of China

    7 shared publications
  • Zhen Chen

    Department of Cardiothoracic Surgery, The Affiliated Hospital of Putian University, Putian, China

    6 shared publications

Latest Publications

  • Open Access

    High comprehensive complication index after minimally invasive esophagectomy associated with poor short-term and long-term outcome: a propensity score matching analysis

    by Xiaoqing Wang, Jingchuan Yu, Shuhan Xie, Ye Lin, Peipei Zhang, Lei Gao, Zhinuan Hong, Mingqiang Kang

    Introduction: The comprehensive complication index (CCI) is a valuable index to comprehensively and systematically evaluate complication severity. This study aimed to evaluate the predictive ability of comprehensive complication index on short- and long-term overall survival(OS) in patients with esophageal squamous cell carcinoma (ESCC) undergoing Mckeown minimally invasive esophagectomy (MIE). Methods: A total of 320 patients treated with radical MIE from 2013 to 2017 were included, and the primary outcome was OS. Firstly, the optimal cut-off value of CCI was determined by X-tile. Propensity score matching(PSM) was used to balance the baseline characteristics. Second, postoperative hospital stay and hospital costs between high- and low-CCI groups were compared. Third, the Kaplan-Meier survival curve was used to analyze survival differences. Fourth, Cox analysis was used to explore the risk factors of OS. Fifth, univariate and multivariate logistic analysis was used to determine the risk factors of high CCI. Results: The patients with CCI > 24.2 was defined as high-CCI group, and those with CCI ≤ 24.2 were assigned to low-CCI group. The high-CCI group had more hospital costs and longer hospital stays than the low-CCI group before and after PSM (both p<0.001). The Kaplan-Meier survival curve indicated that high-CCI group had worse prognosis both before and after PSM (before matching: P<0.001; after matching: P = 0.01). CCI was determined as an independent prognostic factor (before PSM, P = 0.001; after PSM, P = 0.003). Conclusion: The CCI could quantify postoperative complications after esophagectomy. High CCI was associated with longer postoperative hospital stays and expenses and is an independent risk factor for poor OS, holding great vlaue for reference for medical insurance, surgical quality and prognosis management.

  • Open Access

    [Application Value of Neoadjuvant Targeted Therapy in Patients with EGFR-mutant Resectable Lung Adenocarcinoma].

    by Shijie Huang, Mengying Fan, Kaiming Peng, Wanpu Yan, Boyang Chen, Wu Wang, Tianbao Yang, Keneng Chen, Mingqiang Kang, Jinbiao Xie

    The proportion of patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations is relatively high in China. However, these patients currently lack significant benefits from available neoadjuvant treatment options. This study aims to explore the potential application value of neoadjuvant targeted therapy by evaluating its efficacy and safety in patients with EGFR-mutant resectable lung adenocarcinoma. A multicenter retrospective study was used to analyze the treatment effect of patients with stage IIA-IIIB EGFR-mutant lung adenocarcinoma who underwent surgical resection after receiving neoadjuvant targeted therapy from July 2019 to October 2024. A total of 24 patients with EGFR-mutant lung adenocarcinoma from three centers were included in this study. All patients successfully underwent surgery and achieved R0 resection of 100.0%. The objective response rate (ORR) was 83.3% (20/24) . The major pathologic response (MPR) rate was 37.5% (9/24), with 2 patients (8.3%) achieving pathological complete response (pCR). During neoadjuvant therapy, 13 out of 24 patients (54.2%) experienced adverse events of grade 1-2, with no occurrences of ≥ grade 3. The most common treatment-related adverse events were rash (n=4, 16.7%), mouth sores (n=2, 8.3%), and diarrhea (n=2, 8.3%). The median follow-up time was 33.0 months, no deaths occurred in all patients, and the overall survival (OS) rate was 100.0%. The 1-year disease-free survival (DFS) rate was 91.1%, and the 2-year DFS rate remained at 86.2%. The application of neoadjuvant targeted therapy in patients with EGFR-mutant resectable lung adenocarcinoma is safe and feasible, and is expected to become a highly promising neoadjuvant treatment option for the patients with EGFR-mutant lung adenocarcinoma.

  • Open Access

    Causal relationship between type II diabetes mellitus, metformin, insulin, gliclazide, and esophageal cancer—insights from two-sample Mendelian randomization study and meta-analysis

    by Ye Lin, Junhuang Lin, Hui Xu, Zhinuan Hong, Mingqiang Kang

    Background: Over recent decades, findings on the potential correlation between type II diabetes mellitus (T2DM) and the risk of esophageal cancer (EC) have displayed considerable heterogeneity. Furthermore, metformin has emerged as a potentially protective agent against certain site-specific malignancies. This study aims to explore the causal relationship between T2DM, medication treatments (metformin, insulin, gliclazide), and EC risk while addressing the notable variability in previous research findings. Methods: To elucidate the causal associations between T2DM, medication treatments, and EC, we employed a synergistic methodology that integrates the two-sample Mendelian randomization (MR) approach with meta-analysis. The genome-wide association studies (GWAS) pertaining to each exposure and EC were acquired from a publicly accessible database. Results: For MR analyses, three out of seven GWAS datasets within the T2DM cohort exhibited statistical significance. Conversely, all MR analyses yielded non-significant results in the medication cohort. Meta-analyses suggested that a genetic predisposition to T2DM correlated with a reduced risk of EC [odds ratio (OR), 0.999612; 95% confidence interval (CI): 0.999468–0.999756; P=0.01; I2=0%]. Moreover, metformin intake was causally linked to a decreased prevalence of EC (OR, 0.988954; 95% CI: 0.979044–0.998963; P=0.03; I2=0%), whereas neither insulin nor gliclazide manifests statistical significance. Conclusions: Our findings indicate T2DM and metformin are causally associated with diminished risk of EC, while no causal associations exist between insulin, gliclazide, and EC.


  • Open Access

    Prognostic nomogram for overall survival of elderly esophageal cancer patients receiving neoadjuvant therapy: a population-based analysis

    by Kaiming Peng, Hui Xu, Shuhan Xie, Kai Weng, Sjoerd M. Lagarde, Zhinuan Hong, Wenwei Lin, Mingqiang Kang

    Original Article Prognostic nomogram for overall survival of elderly esophageal cancer patients receiving neoadjuvant therapy: a population-based analysis Kaiming Peng, Hui Xu, Shuhan Xie, Kai Weng, Sjoerd M. Lagarde, Zhinuan Hong, Wenwei Lin, Mingqiang Kang


  • Open Access

    Major pathologic response as a prognostic surrogate in esophageal squamous cell carcinoma patients receiving neoadjuvant chemotherapy/chemoimmunotherapy: A multi-center cohort study

    by Zhinuan Hong, Shuhan Xie, Hui Xu, Sunkui Ke, Wenyi Liu, Shijie Huang, Shuchen Chen, Jinbiao Xie, Jinxin Xu, Mingqiang Kang


  • Open Access

    Prognostic value of inflammatory nutritional scores in locally advanced esophageal squamous cell carcinoma patients undergoing neoadjuvant chemoimmunotherapy: a multicenter study in China

    by Jinxin Xu, Zhinuan Hong, Yingjie Cai, Zhen Chen, Jingping Lin, Xi Yuan, Shuchen Chen, Jinbiao Xie, Mingqiang Kang, Sunkui Ke

    Objective: This study investigates the prognostic significance of inflammatory nutritional scores in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC) undergoing neoadjuvant chemoimmunotherapy.Methods: A total of 190 LA-ESCC patients were recruited from three medical centers across China. Pre-treatment laboratory tests were utilized to calculate inflammatory nutritional scores. LASSO regression and multivariate logistic regression analyses were conducted to pinpoint predictors of pathological response. Kaplan-Meier and Cox regression analyses were employed to assess disease-free survival (DFS) prognostic factors.Results: The cohort comprised 154 males (81.05%) and 36 females (18.95%), with a median age of 61.4 years. Pathological complete response (pCR) was achieved in 17.38% of patients, while 44.78% attained major pathological response (MPR). LASSO and multivariate logistic regression analyses identified that hemoglobin, albumin, lymphocyte, and platelet (HALP) (P=0.02) as an independent predictors of MPR in LA-ESCC patients receiving neoadjuvant chemoimmunotherapy. Kaplan-Meier and log-rank tests indicated that patients with low HALP, MPR, ypT1-2, ypN0 and, ypTNM I stages had prolonged DFS (P < 0.05). Furthermore, univariate and multivariate Cox regression analyses underscored HALP (P = 0.019) and ypT (P = 0.029) as independent predictive factors for DFS in ESCC.Conclusion: Our study suggests that LA-ESCC patients with lower pre-treatment HALP scores exhibit improved pathological response and reduced recurrence rate. As a comprehensive index of inflammatory nutritional status, pre-treatment HALP may be a reliable prognostic marker in ESCC patients undergoing neoadjuvant chemoimmunotherapy.


  • Open Access

    Editorial: Frontiers' research topic “advances in esophageal cancer surgery with neoadjuvant therapies”

    by Qi-Xin Shang, Zhi-Nuan Hong, Ming-Qiang Kang, Long-Qi Chen

    Editorial: Frontiers' research topic “advances in esophageal cancer surgery with neoadjuvant therapies”


  • Open Access

    Estimating the cure proportion of stage IA lung adenocarcinoma: a population-based study

    by Zhixin Huang, Dinghang Chen, Zhinuan Hong, Mingqiang Kang

    Background: We aimed to investigate the factors influencing the cure, recurrence, and metastasis rates of stage IA lung adenocarcinoma, using a mixed cure model.Methods: A total of 1,064 patients who underwent video-assisted thoracoscopic pulmonectomy were included. Variable screening was performed using the random forest algorithm and least absolute shrinkage and selection operator approaches. The mixed cure model was used to identify factors affecting patient cure and survival, and a sequential analysis was performed on 5%, 10%, and 20% of the presentational subtype concurrently. A receiver operating characteristics curve was used to determine the best model and construct a nomogram to predict the cure rate.Results: The median follow-up time was 58 (range: 3–115) months. Results from the cure part of the mixed model indicated that the predominant subtype, presentational subtype, and tumor diameter were the main prognostic factors affecting cure rate. Therefore, the nomogram to predict the cure rate was constructed based on these factors. The survival part indicated that the predominant subtype was the only factor that influenced recurrence and metastasis. A sequential analysis of the presentational subtype showed it had no significant effect on survival (P > 0.05). Regardless of the recording mode, no significant improvement was observed in the model's discriminative ability. Only a few postoperative pathological specimens showed lymphovascular invasion (LVI); however, the survival curve suggested a significant effect on patient survival.Conclusions: After excluding the existence of long-term survivors, the predominant tumor subtype was determined to be the only factor influencing recurrence and metastasis. Although LVI is rare in stage IA lung adenocarcinoma, its significance cannot be discounted in terms of determining patient prognosis.


  • Impact of minimally invasive total mesoesophageal excision and minimally invasive esophagectomy on failure patterns of locally advanced esophageal squamous cell carcinoma: a matched cohort study with long-term follow-up

    by Ji-Hong Lin, Shao-Jun Xu, Chao Chen, Cheng-Xiong You, Rui-Qin Chen, Zhi-Fan Zhang, Ming-Qiang Kang, Shu-Chen Chen

    Background The effects of minimally invasive total mesoesophageal excision (MITME) on the long-term prognosis of locally advanced esophageal squamous cell carcinoma (ESCC) remain unknown. The objective of this study was to compare the static and dynamic failure patterns of MITME and minimally invasive esophagectomy (MIE) for locally advanced ESCC. Methods We use propensity score matching (PSM) method to analyze the postoperative failure patterns of the two groups. Cumulative event curves were analyzed for cumulative incidence of failure between different groups, and independent prognostic factors were assessed using time-dependent multivariate analyses. The risk of dynamic failure calculated at 12-month intervals was compared between the two groups using the lifetime table. Results A total of 366 ESCC patients were studied by 1:1 PSM for T stage and TNM stage (MITME group, n = 183; MIE group, n = 183). In the matched cohort, there was significant differences between the MITME and MIE groups in the failure pattern of regional lymph node recurrence (0.5 vs 3.8%, P = 0.032) and non-tumor death (10.9 vs 31.7%, P < 0.001). The cumulative event curve found that the 5-year cumulative failure rate was lower in the MITME group than in the MIE group (3.3 vs 17.1%, P = 0.026) after 5 years of survival. In addition, multivariate Cox regression analysis showed that MIE was an independent poor prognostic factor for a high cumulative failure rate in locally advanced ESCC patients at 5 years after surgery (HR:4.110; 95% CI 1.047–16.135; P = 0.043). The dynamic risk curve showed that the MITME group had a lower risk of failure within 5 years after surgery than the MIE group. Conclusion Considering that MITME can significantly improve the postoperative failure pattern and the benefit lasts for at least 5 years, it is feasible to use MITME as a treatment for locally advanced ESCC.